

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
山崎陽子, 杉野圭史, 佐野 剛, 坂本 晋, 建部順子, 盛田俊介, 本間 栄	特発性肺線維症に対するN-アセチルシステイン吸入療法の有用性と効果発現メカニズムに関する検討	厚生労働科学研究「特発性肺線維症の予後改善を目指したサイクロスポリンならびにN-アセチルシステイン吸入療法に関する臨床研究」班	平成19年度研究報告書	24-31	2008
宮本 篤, 宇留賀公紀, 榎本崇宏, 諸川 納早, 岸 一馬, 本間 栄, 斎木茂樹, 吉村邦彦	気腫性病変を合併し肺容積減少が軽度であった特発性肺線維症の2例	第77回間質性肺疾患研究会討議録		3-12	2008
石田文昭, 佐野 剛, 杉野圭史, 草野英美子, 磯部和順, 坂本 晋, 高井雄二郎, 本間 栄	気腫, 線維化, 混在病態の鑑別における運動負荷試験後の酸素飽和度測定の有用性	第77回間質性肺疾患研究会討議録		40-45	2008
Fujisawa T, Ide K, Holzman MJ, Suda T, Suzuki K, Kuroishi S, Chida K, Nakamura	Involvement of the p38 MARK pathway in IL-13-induced mucous cell metaplasia in mouse tracheal epithelial cells	Respirology	13 (2)	191-202	2008
Uchiyama H, Suda T, Nakamura Y, Gemma H, Toyoshima M, Yasuda K, Inui N, Shirai M, Shirai T, Imokawa S, Ida M, Nakano Y, Sato J, Hayakawa H, Chida K	Alterations in smoking habits are associated with acute eosinophilic pneumonia	Chest	133 (5)	1174-1180	2008
Inui N, Matsui T, Suda T, Chida K	Anti-endothelial cell antibodies in patients with sarcoidosis	Chest	133 (4)	955-960	2008
Enomoto N, Suda T, Uto T, Kato M, Kaida Y, Ozawa Y, Miyazaki H, Kuroishi S, Hashimoto D, Naito T, Fujisawa T, Matsui T, Inui N, Nakamura Y, Sato J, Mizuguchi T, Kato A, Chida K	Possible therapeutic effect of direct haemoperfusion with apolymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia	Respirology	13 (3)	452-460	2008
Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K	Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis	Clin Biochem	41 (13)	1074-1077	2008
Suzuki Y, Miwa S, Shirai M, Ohba H, Murakami M, Fujita K, Suda T, Nakamura H, Hayakawa H, Chida K	Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs	Chest	134 (5)	1027-32	2008
Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsuchihashi Y, Kaneko C, Nukiwa T, Sakatani M, Krischer JP, Nakata K	Japanese Center of the Rare Lung Diseases Consortium. Characteristics of a large cohort of patients with Autoimmune pulmonary Alveolar proteinosis in Japan	Am J Respir Crit Care Med	177 (7)	752-62	2008
Young L, Inoue Y, McCormack FX	Diagnostic potential of serum VEGF-D for lymphangioliomyomatosis	N Engl J Med	358 (2)	199-200	2008
T Arai, Y Inoue, Y Eishi, S Yamamoto, M Sakatani	Propionibacterium Acnes in Granulomas of A patient with necrotising sarcoid granulomatosis	Thorax	63	90-91	2008
Masanori Akira, Kazushige Toyokawa, Yoshikazu Inoue, Toru Arai	Quatitative CT in Chronic Obstructive Pulmonary Disease: Inspiratory and Expiratory Assessment	AJR	192	1-6	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
新井徹, 井上義一, 北市正則	夏型過敏性肺炎	呼吸器科	13	404-411	2008
林田美江, 久保恵嗣, 瀬山邦明, 熊坂利夫, 井上義一, 北市正則, 審良正則	リンパ脈管筋腫症 lymphangioliomyomatosis (LAM) の診断基準	厚生労働省難治性疾患克服研究事業呼吸不全に関する調査研究班	日本呼吸器学会雑誌 46	425-427	2008
林田美江, 藤本圭作, 久保恵嗣, 瀬山邦明, 井上義一	リンパ脈管筋腫症 lymphangioliomyomatosis(LAM) の治療と管理の手引き	厚生労働省難治性疾患克服研究事業呼吸不全に関する調査研究班	日本呼吸器学会雑誌 46	428-431	2008
井上義一	診断と治療のガイドライン ー現行の問題点と展望	呼吸器科	14	81-88	2008
井上義一	まれなびまん性肺疾患. 呼吸器疾患診療マニュアル	日本医師会雑誌	137	240-242	2008
井上義一	特集からむ痰, うっとうしい咳. 治療 慢性呼吸不全・COPD に去痰薬は有効か?	JIM	19	44-48	2009
富岡洋海	特発性間質性肺炎 最新の治療薬開発 ー生命予後の改善を目指してー	呼吸器科	14	109-114	2008
金子正博, 富岡洋海, 金田俊彦, 久保田未央, 谷鎮礼, 藤井宏, 岡崎美樹	FDG-PETにて肺野に多発結節状の集積を認め, その経過を追えたサルコイドーシスの1例	日本呼吸器学会雑誌	46	505-509	2008
Ohtani Y, Ochi J, Mitaka K, Takemura T, Jinta T, Kuramochi J, Miyazaki Y, Inase N, Yoshizawa Y	Chronic Summer-type Hypersensitivity Pneumonitis Initially Misdiagnosed as Idiopathic Interstitial Pneumonia	Internal Medicine	47	857-862	2008
Kishi M, Miyazaki Y, Jinta T, Furusawa H, Ohtani Y, Inase N, Yoshizawa Y	Pathogenesis of cBFL in common with IPF? Correlation of IP-10/TARC ratio with histological patters	Thorax	63	810-816	2008
Tamaoka M, Hassan M, McGovern T, Ramos-Barbon D, Jo T, Yoshizawa Y, Tolloczko B, Hamid Q, Martin JG	The epidermal growth factor receptor mediates allergic airway remodeling in the rat	Eur Respir J	32	1213-1223	2008
Tsuchiya K, Isogai S, Tamaoka M, Inase N, Akashi T, Martin JG, Yoshizawa Y	Depletion of CD8+ T cells enhances airway remodeling in a rodent model of asthma	Immunology	126	45-54	2008
Miyazaki Y, Tateishi T, Akashi T, Ohtani Y, Inase N, Yoshizawa Y	Clinical Predictors and Histologic Appearance of Acute Exacerbations in Chronic Hypersensitivity Pneumonitis	CHEST	134	1265-1270	2008
Takemura T, Akashi T, Ohtani Y, Inase N, Yoshizawa Y	Pathology of hypersensitivity pneumonitis	Curr Opin Pulm Med	14	440-454	2008
Akashi T, Takemura T, Ando N, Eishi Y, Kitagawa M, Takizawa T, Koike M, Ohtani	Histopathological analysis of sixteen autopsy cases of chronic hypersensitivity pneumonitis and comparison with idiopathic pulmonary fibrosis/usual interstitial pneumonia	AJCP			in press
Wang, X., Y. Ohtsuka, K. Kimura, H. Kaji, J. Saito, Y. Tanino, T. Ishida, and M. Munakata	Mannose-binding lectin gene polymorphisms and the development of coal workers' pneumoconiosis in Japan	Am J Ind Med	51 (7)	548-53	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
谷野功典, 王新涛, 佐藤俊, 石井妙子, 猪腰弥生, 仲川奈緒子, 齋藤香恵, 福原敦朗, 齋藤純平, 石田卓, 別役智子, 棟方充	特発性肺線維症における syndecan-4 の役割	分子呼吸器病学	13 (1)	129-132	2009
Takizawa H, Ito K, Umeda A	Increased expression of transforming growth factor - beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease	Am J Respir Crit Care Med	163 (6)	1476-83	2001
Takizawa H	Acute Eosinophilic Pneumonia : Possible Role of Hyperreactivity of Airway Epithelial Cells	Internal Medicine	41 (11)	917	2002
Takizawa H	Bronchial epithelial cells in allergic reactions	Curr Drug Targets Inflamm Allergy	4 (3)	305-1	2005
Takizawa H	Role of mediators in the onset of COPD	Nippon Rinsho	65 (4)	623-7	2007
Fernandez-Real JM, Chico B, Shiratori M, Nara Y, Takahashi H, Ricart W	Circulating surfactant protein A (SP-A), a marker of lung injury, is associated with insulin resistance	Diabetes Care	31	958-963	2008
Nie X, Nishitani C, Yamazoe M, Aiki S, Takahashi M, Shimizu T, Mitsuzawa H, Sawada K, Smith K, Crouch E, Nagae H, Takahashi H, Kuroki Y	Pulmonary Surfactant Protein D Binds MD-2 through the Carbohydrate Recognition Domain	Biochemistry	47	12878-12885	2008
Yamazoe M, Nishitani C, Takahashi M, Katoh T, Aiki S, Shimizu T, Mitsuzawa H, Sawada K, Voelker DR, Takahashi H, Kuroki Y	Pulmonary surfactant protein D inhibits lipopolysaccharide (LPS)-induced inflammatory cell responses by altering LPS binding to its receptors	J Biol Chem	283	35878-35888	2008
高橋弘毅, 千葉弘文, 大塚満雄	間質性肺炎と肺サーファクタント蛋白質	臨床検査	52	899-903	2008
高橋弘毅, 村上聖司, 大塚満雄	特発性間質性肺炎(慢性型, 急性型)	医学と薬学	59	702-707	2008
白鳥正典, 高橋弘毅	呼吸器疾患の臨床検査 up to date 間質性肺炎のマーカー SP-A, SP-D	日胸	67	S31-S35	2008
大塚満雄, 秋山貴由, 西海豊寛, 田中康正, 才善仁樹, 村上聖司, 山田玄, 田中裕士, 高橋弘毅	除湿機が原因と考えられた Thermoactinomyces vulgaris による過敏性肺炎の1例	日呼吸会誌	46	39-43	2008
北田順也, 白鳥正典, 大塚満雄, 工藤和実, 村上聖司, 千葉弘文, 山田玄, 高橋弘毅	特発性間質性肺炎急性増悪に対するステロイドパルス療法後の治療効果および予後の指標としての血清 SP-D	分子呼吸器病	12	57-60	2008
北田順也, 山田玄, 大地貴, 田中紳太郎, 伊藤峰幸, 渡辺敦, 佐藤昌明, 高橋弘毅	LIP, AIHA および気管支アミロイドーシスを合併した原発性シェーグレン症候群の1例	日呼吸会誌	46	960-965	2008
Kanehara M, Yokoyama A, Tomoda Y, Shiota N, Iwamoto H, Ishikawa N, Taooka Y, Haruta Y, Hattori N, Kohno N	Anti-inflammatory Effects and Clinical Efficacy of Theophylline and Tulobuterol in Mild to Moderate Chronic Obstructive Pulmonary Disease	Pulmonary Pharmacology and Therapeutics	21	874-848	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Iwamoto H, Yokoyama A, Shiota N, Shoda H, Haruta Y, Hattori N, Kohno N.	Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype.	Eur Respir J	31	1379-80	2008
Nakashima T, Yokoyama A, Ohnishi H, Hamada H, Ishikawa N, Haruta Y, Hattori N, Tanigawa K, Kohno N.	Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome.	J Intern Med	263	432-439	2008
Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K, Ohshimo S, Fujitaka K, Ohnishi H, Hamada H, Arihiro K, Kohno N.	Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors	Int J Cancer	122	2612-2620	2008
Nakashima T, Yokoyama A, Onari Y, Shoda H, Haruta Y, Hattori N, Naka T, Kohno N.	Suppressor of cytokine signaling 1 inhibits pulmonary inflammation and fibrosis.	J Allergy Clin Immunol	121	1269-1276	2008
Hirata S, Hattori N, Ishikawa N, Fujitaka K, Kumagai K, Taooka Y, Haruta Y, Yokoyama A, Kohno N.	A case of pulmonary asbestosis presenting with temporal arteritis involving multiple medium-sized vessels.	Mod Rheumatol	18	100-4	2008
服部 登, 河野修興	BAL 法の臨床応用	気管支肺胞洗浄 (BAL) の手引き		5-7	2008
服部 登, 河野修興	間質性肺炎の血清マーカー	呼吸器科	13	297-302	2008
服部 登, 河野修興	特発性間質性肺炎: バイオマーカーの有用性と問題点	呼吸器科	14	104-108	2008
石川暢久, 河野修興	薬剤性肺障害	リウマチ科	40 (4)	363-370	2008
石川暢久, 河野修興	間質性肺炎のマーカー・KL-6	日本胸部臨床			2008
石川暢久, 河野修興	腫瘍マーカーのバイオマーカーとしての臨床的意義	医学のあゆみ「肺癌 UPDATE」	224 (13)	1159-1163	2008
西岡安彦, 東 桃代, 青野純典, 曾根三郎	マクロライド薬によりイマチニブの低感受性は克服できるか? - マウス肺線維症モデルにおけるイマチニブの抗線維化作用とマクロライドの併用効果 -	The Japanese Journal of Antibiotics	61	49-53	2008
西岡安彦	内科ガイドライン活用法 - 特発性間質性肺炎 -	内科	102	1174-1180	2008
西岡安彦, 曾根三郎	肺癌 Update - 複数分子を標的とした分子標的治療薬 -	医学のあゆみ	224	1114-1117	2008
Sugita A, Ogawa H, Azuma M, Muto S, Honjo A, Yanagawa H, Nishioka Y, Tani K, Itai A, Sone S.	Antiallergic and Anti-Inflammatory Effects of a Novel IkappaB Kinase beta Inhibitor, IMD-0354, in a Mouse Model of Allergic Inflammation.	Int Arch Allergy Immunol.	148 (3)	186-198	2008
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S.	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.	Cancer Res.	68 (22)	9479-9487	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hanibuchi M, Nishioka Y, Makino H, Koshiba K, Sone S.	A case of Mycobacterium intracellulare pericarditis accompanied with neuro-Sweet disease and pulmonary Mycobacterium intracellulare infection.	Med. Postgrad.	46 (2)	69-73	2008
Wang W, Nishioka Y, Ozaki S, Jalili A, Verma VK, Hanibuchi M, Abe S, Minakuchi K, Matsumoto T, Sone S.	Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells	Lung Cancer	63	23-31	2009
Yamada T, Muguruma H, Yano S, Ikuta K, Ogino H, Kakiuchi S, Hanibuchi M, Uehara H, Nishioka Y, Sone S	Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice	Mol Cancer Ther	8	119-126	2009
Wang W, Nishioka Y, Ozaki S, Jalili A, Abe S, Kakiuchi S, Kishuku M, Minakuchi K, Matsumoto T, Sone S.	HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody	Cancer Immunol Immunother			In press
Yamasawa H, Sugiyama Y, Bando M, Ohno S	Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis	Respiration	75	350-354	2008
Bando M, Takahashi M, Ohno S, Hosono T, Hironaka M, Okamoto H, Sugiyama Y	Torque teno virus DNA titre elevated in idiopathic pulmonary fibrosis with primary lung cancer	Respirology	13	263-269	2008
Tajima S, Soda M, Bando M, Enomoto M, Yamasawa H, Ohno S, Takada T, Suzuki E, Gejyo F, Sugiyama Y	Preventive effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced lung injury in mice	Respirology	13	646-653	2008
Ohno S, Nakaya T, Bando M, Sugiyama Y	Idiopathic pulmonary fibrosis—results from a Japanese nationwide epidemiological survey using individual clinical records	Respirology	13	926-928	2008
Tajima S, Bando M, Ishii Y, Hosono T, Yamasawa H, Ohno S, Takada T, Suzuki E, Gejyo F, Sugiyama Y	Effect of edaravone, a free radical scavenger, on bleomycin-induced lung injury in mice	Eur Respir J	32	1337-1343	2008
Okumura M, Iwai K, Ogata H, Ueyama M, Kubota M, Aoki M, Kokuto H, Tadokoro E, Uchiyama T, Saotome M, Yoshiyama T, Yoshimori K, Yoshida N, Azuma A, Kudoh S	Clinical factors on cavitory and nodular bronchiectatic types in pulmonary mycobacterium avium complex disease	Intern Med	47 (16)	1465-72	2008
Azuma and J Usuki	Invited Review: Novel Therapy of Idiopathic Pulmonary Fibrosis. — How to Evaluate the Efficacy? —	Respir Med CME	1 (2)	75-81	2008
A Azuma, K Hagiwara, S Kudoh	Letter; Basis of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Japanese	Am J Respir Crit Care Med	177	1397-1398	2008
Li YJ, Takizawa H, Azuma A, Kohyama T, Yamauchi Y, Kawada T, Kudoh S, Sugawara I	The effects of oxidative stress induced by prolonged low-dose diesel exhaust particle exposure on the generation of allergic airway inflammation differ between BALB/c and C57BL/6 mice	Immunopharmacology and Immunotoxicology	12	1-15	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
YJ Li, H Takizawa, A Azuma, T Kohyama, Y Yamauchi, S Takahashi, M Yamamoto, T Kawada, S Kudoh, I Sugawara	Disruption of Nrf2 enhances susceptibility to airway inflammatory responses induced by low-dose diesel exhaust particulate in mice	Clin Immunol	128 (3)	366-73	2008
CH Yu, A Azuma, YJ Li, C Wang, S Abe, Usuki, K Matsuda, S Kudoh, T Sunazuka, S Omura	EM703 a New Derivative of Erythromycin, Inhibits TGF-β Signaling in Human Lung Fibroblasts	Exp Lung Res	34 (6)	343-54	2008
C Wang, S Abe, K Matsuda, C Yu, Y Li, J Usuki, A Azuma, S Kudoh	Effects of gefitinib on radiation-induced lung injury in mice	J Nippon Med School	75 (2)	96-105	2008
Y Saito, A Azuma, T Morimoto, K Fujita, S Abe, T Motegi, J Usuki, S Kudoh	Tiotropium Ameliorate Symptoms in Patients with Chronic Airway Mucus Hypersecretion which is Resistant to Macrolide Therapy	Inter Med	47 (7)	585-591	2008
Li YJ, Kawada T, Takizawa H, Azuma A, Kudoh S, Sugawara I, Yamauchi Y, Kohyama T	Airway Inflammatory Responses To Oxidative Stress Induced By Prolonged Low-Dose Diesel Exhaust Particle Exposure From Birth Differ Between Mouse BALB/c And C57BL/6 Strains	Exp Lung Res	34 (3)	125-139	2008
M Yamaya, A Azuma, H Tanaka, H Takizawa, K Chida, Y Taguchi, K Mikasa, J Kadota, S Kudoh	Inhibitory effects of macrolide antibiotics on the hospitalization by exacerbations in COPD patients: a retrospective multicenter analysis	J Am Geriatr Soc	56 (7)	1358-1360	2008
Morimoto T, Azuma A, Abe S, Usuki J, S Kudoh, Sugisaki K, Oritsu M, Nukiwa T	Epidemiology of sarcoidosis in Japan	Eur Respir J	31 (2)	372-379	2008
Enomoto T, Azuma A, Matsumoto A, Nei T, Fujita K, Hattori K, Saito Y, Abe S, Usuki J, and Kudoh S	Preventive effect of sulfamethoxazole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia	Inter Med	47 (1)	15-20	2008
根井貴仁, 川本雅司, 佐藤悦子, 高久多希朗, 瀬尾宜嗣, 森本泰介, 服部久弥子, 齋藤好信, 阿部信二, 白杵二郎, 吾妻安良太, 中山智子, 福田悠, 工藤翔二, 弦間昭彦	急性増悪をきたした特発性上葉限局型肺線維症(網谷病)が疑われた1例	日本呼吸器学会雑誌	47 (2)	116-121	2009
吾妻安良太	特発性肺線維症の新規治療とその評価法	呼吸	28 (2)	203-217	2009
神尾孝一郎, 吾妻安良太	【呼吸器症候群(第2版) その他の呼吸器疾患を含めて】肺循環の異常 肺血管炎 ANCA 関連肺疾患	日本臨床	別冊呼吸器症候群II	391-395	2009
吾妻安良太	日本医科大学内科学講座呼吸器・感染・腫瘍部門 薬剤性肺障害と人種差「グローバル時代の薬剤性肺障害 日本人の特殊性」	Annual Review 呼吸器	2009	123-127	2009
藤田和恵, 吾妻安良太	【呼吸器症候群(第2版) その他の呼吸器疾患を含めて】閉塞性肺疾患, 気管支の異常 閉塞性肺疾患 びまん性汎細気管支炎	日本臨床	別冊呼吸器症候群I	673-677	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
吾妻安良太, 福田悠	【呼吸器症候群(第2版) その他の呼吸器疾患を含めて】びまん性肺疾患 間質性肺炎 蜂巣肺	日本臨床	別冊 呼吸器症候群 I	438-442	2008
榎本達治, 吾妻安良太	【呼吸器症候群(第2版) その他の呼吸器疾患を含めて】びまん性肺疾患 間質性肺炎 特発性器質化肺炎	日本臨床	別冊 呼吸器症候群 I	410-415	2008
森本耕三, 吾妻安良太	【リウマチ医が知るべき関節リウマチの呼吸器合併症 その診断・治療・予防】細気管支炎(解説/特集)	リウマチ科	40 (4)	380-385	2008
田中貴久, 根井貴仁, 白杵二郎, 松本亜紀, 森本泰介, 神尾孝一郎, 斉藤好信, 阿部信二, 吾妻安良太, 工藤翔二, 弦間昭彦, 功刀しのぶ, 許田典男, 福田悠	CPC 日常臨床から学ぶ この症例の新しい意義は? 間質性肺炎の長期経過中に複数の感染症を併発し死亡した1例(症例検討会/症例報告)	THE LUNG-perspectives	16 (3)	314-320	2008
藤田和恵, 舘田一博, 吾妻安良太, 工藤翔二	【抗菌薬選択のポイント】抗菌薬の特性から考えること マクロライド系抗菌薬(解説/特集/抄録あり)	化学療法の領域	24 巻 増刊	202-211	2008
千葉弘文, 吾妻安良太	Pro&Con 薬剤性肺障害は日本人に高頻度に発生するか?(解説)	THE LUNG-perspectives	16 (2)	255-263	2008
松本亜紀, 吾妻安良太	【新しい喘息治療の可能性】マクロライドとは? マクロライドについて教えてください(Q&A/特集)	Q&A でわかるアレルギー疾患	4 (2)	185-187	2008
吾妻安良太	呼吸器疾患における医師主導臨床試験の取り組みと将来展望】肺線維症 NAC, CyA, PMX 好中球吸着療法(解説/特集)	分子呼吸器病	12 (2)	116-122	2008
吾妻安良太	より豊かな生活に貢献する医療技術に関する研究 びまん性肺疾患の医師主導臨床試験におけるオンライン患者登録システムの構築(原著論文/抄録あり)	医科学応用研究財団研究報告	25	26-29	2008
森本泰介, 吾妻安良太, 工藤翔二	疾患の病因と病態 サルコイドーシスの最近の疫学(総説)	Annual Review 呼吸器	2008	137-141	2008
吉村邦彦, 安斎千恵子, 衛藤義勝	わが国の嚢胞性線維症患者における責任 CFTR 遺伝子変異の解析	厚生労働科学研究費補助金(難治性疾患克服研究事業)分担研究報告書	平成19年度総括・分担研究報告書	263-265	2008
吉村邦彦, 安斎千恵子, 衛藤義勝	わが国の嚢胞性線維症患者における責任 CFTR 遺伝子変異の解析	厚生労働科学研究費補助金(難治性疾患克服研究事業)分担研究報告書	平成17年度～19年度総合分担研究報告書	300-303	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
成瀬 達, 石黒 洋, 玉腰暁子, 吉村邦彦, 広田昌彦, 大槻 眞	脾嚢胞線維症の診断マニュアルの作成	厚生労働科学研究費補助金(難治性疾患克服研究事業)分担研究報告書	平成19年度総括・分担研究報告書	147-150	2008
成瀬 達, 石黒 洋, 玉腰暁子, 吉村邦彦, 広田昌彦, 大槻 眞	第3次脾嚢胞線維症全国疫学調査	厚生労働科学研究費補助金(難治性疾患克服研究事業)分担研究報告書	平成17年度～19年度総合分担研究報告書	205-215	2008
諸川納早, 宮本 篤, 宇留賀公紀, 榎本崇宏, 高谷久史, 岸 一馬, 吉村邦彦	特発性肺繊維症増悪時における血漿 BNP 値の臨床的検討	厚生労働科学研究 特発性肺線維症の予後改善を目指したサイクロステロイド療法ならびにNアセチルシステイン吸入療法に関する臨床研究	平成19年度研究報告書	107-109	2008
宮本 篤, 宇留賀公紀, 高谷久史, 榎本崇宏, 諸川納早, 岸 一馬, 吉村邦彦	特発性間質性肺炎合併肺癌患者の外科手術に関する実態調査	厚生労働科学研究費補助金 難治性疾患克服研究事業 びまん性肺疾患に関する調査研究班	平成19年度研究報告書	62-66	2008
吉原久直	シリカ肺傷害モデルに対して気道内 KGF 強制発現が及ぼす病態抑制効果	帝京医学雑誌	31 (1)	43-53	2008
小島康弘	びまん性肺疾患における気管支肺胞洗浄液中液性因子の網羅的検討	帝京医学雑誌	32 (1)	59-70	2009
Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, Nakae S, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M.	An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor	J Immunol	181 (9)	5981-9	2008
Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, Saito H, Matsushima K, Ohta K, Yamamoto K, Yamaguchi M	Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils.	Lab Invest	88 (11)	1245-53	2008
Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T	Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin	Lung Cancer	62	45-54	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kadowaki T, Hamada H, Miyoshi S, Hamaguchi N, Sakai K, Ito R, Yasutake-Oshima M, Higaki J, Kito K	Refractory pneumothorax secondary to lung cancer in a patient with idiopathic pulmonary fibrosis	Intern Med	47	1251-1254	2008
濱田泰伸	過敏性肺炎とその周辺疾患 ベリリウム症：過敏性肺炎との比較	呼吸器科	13	449-453	2008
戸井孝行, 伊東亮治, 濱田泰伸, 酒井希美子, 濱口直彦, 門脇徹, 三好誠吾, 檜垣實男, 阿部聖裕	間質性肺炎を経過観察中に診断した myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) 関連血管炎の1例	日内会誌	97	803-806	2008
三好誠吾, 濱田泰伸, 片山 均	原発性空洞の形成を観察しえたサルコイドーシスの1例	日呼吸会誌	46	341-345	2008

書 籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
本間 栄	特発性肺線維症 呼吸機能	泉 孝英編	新しい診断と治療の ABC	最新 医学社	大阪	2008	61-70
坂本 晋, 本間 栄 (分担)	今後の生理検査に望むこと: 呼気凝集検査	安倍信行, 竹中 克, 永江 学, 信岡祐彦編	これから広がる生理 検査・新たにはじま る生理検査, 検査と 技術	医学書院	東京	2008	1164-1166
本間 栄	チアノーゼとばち指	工藤翔二, 相澤久道, 太田 健, 川崎一輝, 弦間昭彦, 酒井文和, 中田紘一郎, 永武 毅, 貫和敏博編	呼吸器疾患診療マ ニュアル 日本医師 会雑誌 137・特別号			2008	88
本間 栄, 杉野 圭史, 坂本 晋 (分担)	閉塞性細気管支炎症候群	工藤翔二, 中田紘一郎, 永井厚志, 太田 健編	呼吸器症候群	日本 臨床社	東京	2008	682-685
佐野 剛, 本間 栄 (分担)	びまん性誤嚥性細気管支炎	工藤翔二, 中田紘一郎, 永井厚志, 太田 健編	呼吸器症候群	日本 臨床社	東京	2008	669-672
高井雄二郎, 本間 栄 (分担)	急性上気道閉塞	工藤翔二, 中田紘一郎, 永井厚志, 太田 健編	呼吸器症候群	日本 臨床社	東京	2008	622-625
北市正則, 玉舎 学, 杉本親寿, 大塚淳司, 新井 徹, 井上義一, 林 清二	病理ー特発性肺線維症 (IPF)の臨床経過, 画像 所見と整合性のある病理 診断は可能かをめぐって ー第2章 病理・病態生 理. 新しい診断と治療 のABC55/呼吸器7 特 発性肺線維症		2008年最新医学別冊	(株)最新 医学社		2008	25-32
井上義一	治療薬剤:(1)ステロイド 剤・免疫抑制薬. 第4章 管理・治療. 新しい診断 と治療のABC55/呼吸器 7 特発性肺線維症		2008年最新医学別冊	(株)最新 医学社		2008	113-120
井上義一, 山田佳子	C. BAL 法の手技:[BAL] 法の手引き	日本呼吸器 学会びまん 性肺疾患学 術部会	厚生労働省難治性疾 患克服研究事業びま ん性肺疾患調査研究 班	(株)克誠 堂出版	東京都	2008	113-120
新井 徹, 井上義一	アミロイドーシスと Wegener 肉芽腫症. 第 XI 章 各種疾患の気管支鏡 所見 8.		気管支鏡ー臨床医の ためのテクニックと 画像診断 第2版	(株)医学 書院		2008	218-221
井上義一	じん肺. 第 XI 章 各種疾患 の気管支鏡所見 11.		気管支鏡ー臨床医の ためのテクニックと 画像診断 第2版	(株)医学 書院		2008	226-228
井上義一	肺胞蛋白症. 第 XI 章 各種 疾患の気管支鏡所見 17.		気管支鏡ー臨床医の ためのテクニックと 画像診断 第2版	(株)医学 書院		2008	240-245

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
井上義一	肺砲たんぱく症		ホームメディカ新版 家庭医学大事典	(株)小学館		2008	1315
井上義一	肺ランゲルハンス細胞組織球症(肺好酸球性肉芽腫症, ヒストオサイトーシスX)		ホームメディカ新版 家庭医学大事典	(株)小学館		2008	1316
井上義一	リンパ脈管筋腫症(肺リンパ脈管筋腫症)		ホームメディカ新版 家庭医学大事典	(株)小学館		2008	1316-1317
井上義一	グッドパスチャー症候群		ホームメディカ新版 家庭医学大事典	(株)小学館		2008	1318
井上義一	肺アミロイドーシス		ホームメディカ新版 家庭医学大事典	(株)小学館		2008	1318-1319
井上義一	肺胞微石症		ホームメディカ新版 家庭医学大事典	(株)小学館		2008	1319
井上義一	薬剤性肺障害をいかに防ぐか, Topic 原因から考える対策, 診断のポイントとピットフォール		呼 吸 器 NEWS & VIEWS, 33, 2008 Winter No. 33	ライフサイエンス出版(株)		2008	3-7
井上義一, 新井 徹, 審良正則, 北市正則	非特異性間質性肺炎, 呼吸器症候群(第2版)(I) - その他の呼吸器疾患を含めて - 別冊		日本臨牀新領域別症候群シリーズ No8 第2版	(株)日本臨牀社発行		2008	3-7
富岡洋海	薬剤性肺障害	石原享介					
谷口博之, 藤田次郎	呼吸器病レジデントマニュアル第4版			医学書院	東京	2008	373-376
富岡洋海	特発性肺線維症 経過・予後	泉孝英	新しい診断と治療のABC 55 呼吸器7 特発性肺線維症	最新医学社	大阪	2008	154-162
高橋弘毅, 白鳥正典	特発性肺線維症 (2) 血液診断	泉孝英編	最新医学別冊 新しい診断と治療のABC	最新医学社	東京	2008	71-78
白鳥正典, 高橋弘毅	液性成分の分析と評価		日本呼吸器学会, 気管支肺胞洗浄[BAL]法の手引き	克誠堂出版	東京	2008	211-24
西岡安彦, 曾根三郎	特発性肺線維症	工藤翔二	別冊日本臨床 呼吸器症候群(第2版)	日本臨床社	東京	2008	416-420
西岡安彦, 曾根三郎	肺癌	日本呼吸器学会びまん性肺疾患学術部会, 厚生労働省難治性疾患克服事業びまん性肺疾患調査研究班	気管支肺胞洗浄(BAL)法の手引き	南山堂	大坂	2008	106-108
吉村邦彦	びまん性汎細気管支炎/びまん性気管支拡張症	今日の治療方針2008	山口 徹, 北原光夫, 福井次矢 編集	医学書院		2008	216-218
吉村邦彦	呼吸器症候群(第2版) I- その他の呼吸器疾患を含めて - III 閉塞性肺疾患・気管支の異常 A. 閉塞性肺疾患 嚢胞性線維症	別冊日本臨牀新領域別症候群シリーズ No. 8				2008	654-663

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ
吉村邦彦	病因、特発性肺線維症、 新しい診断と治療の ABC 55、呼吸器 7	最新医学別冊	泉 孝英 編	最新 医学社	東京	2008	41-50
長瀬洋之、 大田 健	IGF-1 と呼吸器疾患	Annual Review 呼吸器 2008		中外 医学社		2008	40-43

研究成果の刊行物・別刷

Beneficial Effect of Polymyxin B-immobilized Fiber Column (PMX) Hemoperfusion Treatment on Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Yoshitsugu Seo¹, Shinji Abe¹, Misuzu Kurahara¹, Daisuke Okada², Yoshinobu Saito¹, Jiro Usuki¹, Arata Azuma¹, Kiyoshi Koizumi³ and Shoji Kudoh¹

Abstract

Objective This study was aimed to investigate the effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on the acute exacerbation of idiopathic pulmonary fibrosis (IPF).

Patients and Methods Six patients with a clinical diagnosis of idiopathic pulmonary fibrosis (IPF) who developed acute exacerbation were included in this study. Although five of six patients were treated with high-dose corticosteroid therapy, mechanical ventilation was necessary for all six patients due to severe respiratory failure. Blood endotoxin levels were undetectable in all patients. PMX treatment was performed on these six patients.

Results In four of six patients, alveolar-arterial difference of oxygen (AaDO₂), serum KL-6 and lactate dehydrogenase (LDH) were improved after PMX treatment. These four patients were successfully weaned from mechanical ventilation and survived more than 30 days after the initial PMX treatment.

Conclusion These data suggest a potential beneficial effect of PMX treatment on acute exacerbation of IPF.

Key words: acute exacerbation of idiopathic pulmonary fibrosis, polymyxin B-immobilized fiber column (PMX) treatment, alveolar-arterial difference of oxygen (AaDO₂), KL-6, lactate dehydrogenase (LDH)

(DOI: 10.2169/internalmedicine.45.6018)

Introduction

Idiopathic interstitial pneumonias (IIPs) represent a heterogeneous group of diffuse parenchymal lung disorders of unknown etiology. Idiopathic pulmonary fibrosis (IPF) is among the most common IIP and is characterized by clinically progressive dyspnea and worsening of pulmonary function (1, 2). Some IPF patients have acute exacerbations generally characterized by severe respiratory failure and pathological lesions of diffuse alveolar damage (DAD) (3-7). Mortality of these patients with acute exacerbation has been reported to be high during their hospitalization (4-6).

Polymyxin B-immobilized fiber (PMX) treatment has been reported to be effective in both gram-negative and

gram-positive sepsis (8). Recent reports have suggested that PMX treatment may improve oxygenation in patients with acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) (9-11). In this study, we investigated whether direct hemoperfusion with PMX could be effective in acute exacerbation of clinical IPF patients. Analyses of alveolar-arterial difference of oxygen (AaDO₂), serum KL-6, serum lactate dehydrogenase (LDH) and survival for more than 30 days after PMX treatment were performed to evaluate its effectiveness in acute exacerbation of IPF.

Patients and Methods

Six patients with acute exacerbation of IPF were enrolled in an open-label pilot trial of hemoperfusion treatment with

¹The 4th Department of Internal Medicine, Nippon Medical School, Tokyo, ²Aizu Chuo Hospital, Aizuwakamatsu, Fukushima and ³The 2nd Department of Surgery, Nippon Medical School, Tokyo

Received for publication April 26, 2006; Accepted for publication June 16, 2006

Correspondence to Dr. Shinji Abe, The 4th Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi Bunkyo-ku, Tokyo 113-8603

the PMX column. IPF was defined clinically according to the criteria of the American Thoracic Society/European Respiratory Society (ATS/ERS) international consensus statement (1, 2): 1) exclusion of other known causes of diffuse lung diseases, such as environmental exposure, drug toxicities and collagen vascular diseases (CVD). The presence of CVD was excluded by means of detailed history, clinical examination and the following serum test: anti-neutrophil cytoplasmic antibody (MPO-, and PR3-ANCA), anti-nuclear and anti-DNA antibodies, rheumatoid factor and angiotensin-converting enzyme; 2) abnormal pulmonary function studies, including evidence of restriction, impaired gas exchange, decreased diffusing capacity of the lung for CO (DL_{CO}); 3) High resolution computed tomography (HRCT) scan showing reticular opacities, honeycombing and traction bronchiectasis with basal and peripheral predominance in the absence of atypical features for IPF, such as peribronchovascular nodules, micronodules, isolated cysts and consolidation; 4) age >50 years; 5) insidious onset of otherwise unexplained dyspnea on exertion; 6) duration illness of >3 months; 7) persistent bibasilar, inspiratory crackles; 8) transbronchial biopsy specimens in all cases showing no features incompatible with a diagnosis of IPF. Based on these clinical criteria, the diagnosis of IPF has been reported to be correct in more than 90% (12).

Acute exacerbation of IPF was defined as follows (3, 4): exacerbation of dyspnea within one month, newly developing diffuse pulmonary opacities on chest radiographs, decrease in arterial oxygen tension (PaO₂) of more than 10 mmHg under similar conditions, and absence of heart failure or an identified infectious agent. All of the above criteria were satisfied in all cases. To rule out congestive heart failure, ultrasound cardiography was performed. None of the patients had evidence of left ventricular dysfunction. Cultures of sputum, blood and urine to detect bacteria, fungus and mycobacterium were negative in all patients. Serological test for *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, Legionella, and various viruses (cytomegalovirus, herpes simplex, adenovirus, influenza virus, parainfluenza virus, and respiratory syncytial virus) were negative. Blood endotoxin levels were determined by the *Endospecy* test using the new perchloric acid method described previously (8, 9). The upper normal limit was 1.0 pg/ml. High resolution computed tomography (HRCT) of the thorax was carried out on all six patients just before PMX treatment. The difference between alveolar and arterial oxygen tension (AaDO₂) was calculated with the use of a simplified form of the alveolar gas equation: partial pressure of alveolar oxygen=partial pressure of inspired oxygen (partial pressure of arterial carbon dioxide÷R), where R, the respiratory quotient, was assumed to be 0.8. The arterial oxygen tension (PaO₂)/inspiratory oxygen fraction (FiO₂) (P/F) ratio was also calculated. Serum KL-6 and LDH were assessed by enzyme-linked immunoadsorbent assay (ELISA) to evaluate PMX treatment. For venous access, a double-lumen catheter (Arrow International Inc., Reading, PA) was inserted into the femoral vein

using Seldinger's method as described previously (8-10). Direct hemoperfusion with PMX (Toraymyxin 20R, Toray Medical Co., Tokyo, Japan) was carried out at a flow rate of 80-100 ml/min 1-5 times for 2-6 hours. There have been varied reports on the length of the treatment and how many times PMX treatment should be performed (8, 9, 13). In this study, patients were started on PMX therapy at different time points. Therefore the period of PMX treatment varied, depending on the patient's condition. Nafamostat mesilate (Torii Pharma Co., Tokyo, Japan) was used as an anti-coagulant during the PMX treatment. It has been reported that the half-life of nafamostat is 8 minutes and anti-coagulant effects are observed only in the extra-corporeal circuit (8, 9). PMX treatment was initiated when respiratory failure progressed even though the patients were treated with high-dose corticosteroid therapy (1 g of methylprednisolone given IV for three days). To evaluate the effect of PMX treatment, conventional therapies were not changed pre- and post-PMX treatment. A PaO₂ of greater than 60 mmHg with ≤35% oxygen was considered to be an indication for weaning from mechanical ventilation. PMX treatment was stopped only if the patient died, or was successfully weaned from ventilation. Previous reports have used 30-day mortality after an episode of ARDS (9, 14). We evaluated the 30-day survival rate after the initiation of PMX treatment. The survivors were followed by primary physicians for at least 90 days after PMX treatment. Written informed consent was obtained from each patient or guardian. The study was approved by the Ethics Committee of Nippon Medical School.

Results

The clinical characteristics before PMX treatment and patient outcomes are listed in Table 1. There were four males and two females, aged 57-79 (average 67) years. Four patients (cases 1, 4, 5 and 6) were ex-smokers. The duration of symptoms before acute exacerbation averaged 29 months (range, 3-72 months). Four patients (cases 1, 3, 4 and 5) were receiving corticosteroid (prednisolone; PSL) therapy (40 mg/day, 10 mg, 10 mg and 30 mg, respectively). Case 3 underwent immunosuppressive therapy with cyclophosphamide (CPA). Two patients (cases 2 and 4) were receiving inhalation of *N*-acetylcystein (NAC). Serum KL-6, a marker of lung injury and fibrosis (15) was elevated to 1030-3700 IU/ml (normal range <500 IU/ml) before PMX therapy. Serum LDH was elevated to 439-746 (normal range <250 IU/ml). AaDO₂ was elevated to 392-550 mmHg and P/F (PaO₂/FiO₂) ratio was decreased to 50-246 (normal range >300) (mmHg). We assessed the sputum, urine, and blood cultures and serum beta-D-glucan in order to exclude bacterial and fungal infection. Although case 3 was positive for serum beta-D-glucan (24.0) before PMX treatment, no organisms were detected in any patient. Blood endotoxin levels and D-dimer were within normal limits in all six patients. HRCT of the thorax before PMX treatment showed diffuse parenchymal opacifications consistent with acute ex-

Table 1. Characteristics and Outcome of the Patients

case	sex/age	duration (months)	P/F	AaDO ₂ (mmHg)	LDH (U/ml)	KL-6 (U/ml)	ES/ β -DG (pg/ml)	previous therapy	outcome*
1	M/61	3	93	443	498	3700	<0.8/<5.0	PSL 40mg	alive
2	F/73	72	180	392	439	1690	<0.8/<5.0	NAC	alive
3	F/67	36	109	515	652	1030	<0.8/ 24.0	PSL 10mg+CPA 50mg	died at day 18
4	M/64	48	50	550	518	2420	<0.8/<5.0	PSL 10mg+NAC	died at day 7
5	M/57	14	180	359	413	2610	<0.8/<5.0	PSL 30mg	alive
6	M/79	3	246	397	746	1488	<0.8/<5.0	none	alive

β -DG= β -D-glucan, CPA=cyclophosphamide, ES=endotoxin, NAC=inhalation of N-acetylcystein, PSL=prednisolone

*survival more than thirty days after the initial PMX treatment




Figure 1. Serial AaDO₂ and serum LDH values pre- and post-PMX treatment (cases 1-6). PMX treatment resulted in improved AaDO₂ and serum LDH in four (cases 1, 2, 5 and 6) of six patients with acute exacerbation of clinical IPF.

acerbation of IPF (4) in all six patients.

Oxygenation including AaDO₂ and P/F ratio was improved during PMX treatment in four of six patients. Those four patients (cases A-F) were successfully weaned from

mechanical ventilation and survived more than 30 days after initial PMX treatment. AaDO₂, serum KL-6 and LDH were improved in the survivors post PMX treatment.

In case 1, we performed PMX treatment five times for 2




Figure 2. Chest X-ray and HRCT of case 1. (A) Chest X-ray shows bilateral infiltration in the lower lung at the time of acute exacerbation of clinical IPF. (B) Chest X-ray shows improved bilateral infiltration, and an increase in lung volume after treatment with PMX treatment five times. (C) Reticular and linear patterns with traction bronchoectasis and ground glass attenuation were observed in the acute exacerbation of IPF (before PMX treatment). (D) Ground glass attenuation was resolved after PMX treatment.




Figure 3. Serum KL-6 levels pre- and post-PMX-treatment in clinical IPF patients with acute exacerbation. Serum KL-6 levels post PMX were not evaluated in cases 3 and 4.

hours each. Acute hypoxemic respiratory failure assessed by AaDO₂, P/F ratio, serum LDH and KL-6 gradually improved after each PMX treatment (Fig. 1A). Diffuse ground glass attenuation of HRCT resolved after five times treatment with PMX in case 1 (Fig. 2). This patient has survived more than 20 months with oxygen (O₂) therapy. In case 2, we per-

formed PMX treatment once for six hours. As shown in Fig. 1B, AaDO₂ and LDH were dramatically improved after PMX treatment. The patient was weaned from mechanical ventilation 8 days after acute exacerbation and survived more than 30 days after PMX treatment. However, this patient died of acute myocardial infarction after 3 months of PMX treatment without evidence of respiratory failure. In cases 3 and 4, we administered PMX treatment once for two hours. In case 3 (Fig. 1C), although PaO₂ and AaDO₂ were temporarily improved during PMX treatment, the patient finally died of disseminated intravascular coagulation (DIC) eighteen days after acute exacerbation. In case 4 (Fig. 1D), high-dose corticosteroid therapy was administered after PMX treatment because of a severe esophageal ulcer. AaDO₂ was slightly decreased after PMX treatment. However, the patient died of respiratory failure due to progression of IPF seven days after acute exacerbation. Autopsy lung specimens in case 4 showed typical honeycomb change of usual interstitial pneumonia (UIP) with DAD. Treatment with PMX was discontinued because patients died (cases 3 and 4). In cases 5 (Fig. 1E) and 6 (Fig. 1F), we administered PMX treatment twice for 2 hours as originally described (8, 9). AaDO₂ and LDH were improved and these patients were weaned from mechanical ventilation and survived more than

30 days post PMX treatment. In the four of six patients who survived, serum KL-6 levels decreased in response to PMX treatment (Fig. 3).

Discussion

In this pilot study, we demonstrated the potential beneficial effect of PMX treatment for acute exacerbations of clinical IPF patients.

The prognosis of IPF is known to be poor. The mean length of survival varies from 3 to 5 years, and the major cause of death is respiratory failure due to IPF progression (1, 2). Respiratory failure may ensue, in which case IPF patients are generally difficult to ventilate and are rarely successfully weaned from mechanical ventilation. In one study of seven mechanically ventilated patients with IPF, six of seven patients died after 3.2 ± 4 days of ventilation (16). Fumeaux et al reported fourteen patients with idiopathic or secondary pulmonary fibrosis died in the ICU after a mean stay of 7.6 ± 4.6 days, despite mechanical ventilation (17). Acute exacerbations of IPF have been described high mortality in several reports (4, 5, 7, 18). Ambrosini et al reported that four of five patients with IPF died a median of 13 days after onset of acute exacerbation (5). Parambil et al recently reported that six of seven patients with acute exacerbation of IPF undergoing surgical lung biopsy died during their hospitalization (7). In the current study, four of six patients with acute exacerbation who required mechanical ventilation survived more than 30 days after the initial PMX treatment, suggesting a clinical benefit of PMX treatment.

Several papers have reported the effect of PMX treatment on oxygenation (8-11). Similar results were observed in this study. In four of six patients, AaDO₂ and P/F ratio improved after PMX treatment even though the endotoxin levels were all below the normal range. Aoki et al have suggested that reduction of endotoxin concentration might reduce pulmonary vasoconstriction and intrapulmonary shunting (8). Nakamura et al have reported that the blood metalloproteinase (MMP)-9 level and tissue inhibitor of MMP (TIMP)-1 level were significantly reduced after PMX treatment and were well correlated with improvement of P/F ratio (10). In an animal model of sepsis, PMX has been reported to improve oxygenation through suppression of nitric oxide production (19). The precise mechanisms by which PMX treatment improves oxygenation still remain unsolved. In this pilot study, there was no limitation of patient management without PMX treatment and minor differences in infusion therapy may have affected the oxygenation of patients. However, conventional therapies were not changed at any stage during each PMX treatment, thus allowing the effect of PMX treatment to be evaluated.

Acute exacerbation of IPF is characterized pathologically

by DAD, which clinically resembles ALI/ARDS. Complicating factors including inflammatory mediators probably contribute to DAD (20, 21). We measured the serum levels of inflammatory cytokines (IL-6, IL-10), the chemokine IL-8 and plasma plasminogen activator inhibitor 1 (PAI-1) in cases 1, 2 and 4. Serum IL-6, IL-8 and plasma PAI-1 decreased in cases 1 and 2, which responded to PMX treatment (data not shown). Serum levels of the anti-inflammatory cytokine IL-10 increased after PMX treatment in these two patients. It is still unknown whether PMX has an effect on cytokine/chemokine or PAI-1 production. Kushi et al recently reported that improvement of P/F ratio by PMX treatment was related to the decrease in blood neutrophil elastase and IL-8 (11). Inflammatory cells including activated monocytes producing such mediators may be absorbed by PMX treatment (22, 23). Serum LDH has been demonstrated to be a useful indicator of lung damage or inflammation (24). Serum KL-6 has also been reported to be a useful marker of the rapid progression of IPF (15). In this study, these two markers tended to be correlated with AaDO₂. The effect of PMX on these markers also remains unclear.

There is some controversy regarding the choice of appropriate cycles and frequencies of PMX treatment. Aoki et al have reported once to seven times for the treatment of sepsis (8). Additionally, PMX treatment once or twice for 4 hours has reportedly improved the survival of sepsis patients (13). A recent paper has suggested that frequent treatment might be effective in severe sepsis patients (25). We performed PMX treatment 1-5 times for 2 or 6 hours, depending on the patient's condition. Further investigation will be needed to determine and confirm the cycles and frequencies of PMX treatment.

The present results suggest that PMX therapy could be of benefit in patients with acute exacerbation of IPF. This study is a pilot study, mainly designed to rescue the patients and to assess the effectiveness of PMX treatment. However, the small number of patients and the absence of control groups are considerable limitations of the study. A randomized controlled study will be needed.

Abbreviations:

AaDO₂=alveolar-arterial difference of oxygen

ALI=acute lung injury

ARDS=acute respiratory distress syndrome

DIC=disseminated intravascular coagulation

HRCT= high resolution computed tomography

LDH=lactate dehydrogenase

PAI-1= plasminogen activator inhibitor 1

P/F=arterial oxygen tension (PaO₂)/inspiratory oxygen fraction (FiO₂)

PMX=polymyxin B-immobilized fiber

UIP= usual interstitial pneumonia

References

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. *Am J Respir Crit Care Med* **165**: 277-304, 2002 (Erratum in: *Am J Respir Crit Care Med* **166**: 426, 2002).
2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). *Am J Respir Crit Care Med* **161**: 646-664, 2000.
3. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathological finding in three cases. *Chest* **103**: 1808-1812, 1993.
4. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. *AJR Am J Roentgenol* **168**: 79-83, 1997.
5. Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. *Eur Respir J* **22**: 821-826, 2003.
6. Rice AJ, Wells AU, Bouros D, et al. Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study. *Am J Clin Pathol* **119**: 709-714, 2003.
7. Parambil JG, Myers JL, Ryu JH. Histopathological features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. *Chest* **128**: 3310-3315, 2005.
8. Aoki H, Kodama M, Tani T, Hanasawa K. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. *Am J Surg* **167**: 412-417, 1994.
9. Tsushima K, Kubo K, Koizumi T, et al. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. *J Clin Apher* **17**: 97-102, 2002.
10. Nakamura T, Kawagoe Y, Matsuda T, et al. Effect of polymyxin B-immobilized fiber on blood metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in acute respiratory distress syndrome patients. *Blood Purif* **22**: 256-260, 2004.
11. Kushi H, Miki T, Okamoto K, Nakahara J, Saito T, Tanjoh K. Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. *Crit Care* **9**: R653-R661, 2005.
12. Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. *Chest* **116**: 1168-1174, 1999.
13. Nemoto H, Nakamoto H, Okada H, et al. Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. *Blood Purif* **19**: 361-369, 2001.
14. Baughman RP, Gunther KL, Rashkin MC, Keeton DA, Pattishall EN. Changes in the inflammatory response of the lung during acute respiratory distress syndrome: prognostic indicators. *Am J Respir Crit Care Med* **154**: 76-81, 1996.
15. Yokoyama A, Kohno N, Hamada H, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* **158**: 1680-1684, 1998.
16. Nava S, Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. *Thorax* **54**: 390-395, 1999.
17. Fumeaux T, Rothmeier C, Jolliet P. Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis. *Intensive Care Med* **27**: 1868-1874, 2001.
18. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. *Am J Med* **88**: 396-404, 1990.
19. Yamamoto H, Koizumi T, Kaneki T, et al. Direct hemoperfusion with polymyxin B-immobilized fiber improves shock and hypoxemia during endotoxemia in anesthetized sheep. *J Endotoxin Res* **8**: 419-426, 2002.
20. Ward PA. Role of complement, chemokines, and regulatory cytokines in acute lung injury. *Ann NY Acad Sci* **796**: 104-112, 1996.
21. Welty-Wolf KE, Carraway MS, Ortel TL, Piantadosi CA. Coagulation and inflammation in acute lung injury. *Thromb Haemost* **88**: 17-25, 2002.
22. Tsujimoto H, Ono S, Hiraki S, et al. Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+CD14+ monocyte monocytes in patients with septic shock. *J Endotoxin Res* **10**: 229-237, 2004.
23. Ono S, Tsujimoto H, Matsumoto A, Ikuta S, Kinoshita M, Mochizuki H. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. *Am J Surg* **188**: 150-156, 2004.
24. Drent M, Cobben NA, Henderson RF, Wouters EF, van Diejen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. *Eur Respir J* **9**: 1736-1742, 1996.
25. Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. *Shock* **23**: 400-405, 2005.

Preventive Effect of Sulfamethoxazole-trimethoprim on *Pneumocystis jiroveci* Pneumonia in Patients with Interstitial Pneumonia

Tatsuji Enomoto^{1,2}, Arata Azuma², Aki Matsumoto², Takahito Nei², Kazue Fujita², Kumiko Hattori^{1,2}, Yoshinobu Saito², Shinji Abe², Jiro Usuki² and Shoji Kudoh²

Abstract

Background *Pneumocystis jiroveci* pneumonia (PCP) is a potentially fatal complication in interstitial pneumonia patients receiving glucocorticoid therapy. Prophylaxis of PCP during glucocorticoid therapy is an important issue in the treatment of interstitial pneumonia.

Objective We evaluated the prophylactic effect of sulfamethoxazole-trimethoprim (TMP-SMX) in interstitial pneumonia patients receiving glucocorticoids.

Methods We retrospectively analyzed 74 interstitial pneumonia patients who received glucocorticoid therapy.

Results Seven of the 74 patients developed PCP. At the time of diagnosis of PCP, the mean duration of glucocorticoid therapy was 71 days and the mean daily dose of prednisolone was 37 mg. Among the 7 patients, the circulating CD4+ lymphocyte count was 370/ μ l on average and it was over 200/ μ l in 3 cases. The PCP patients showed a significant reduction of the lymphocyte count at 4 weeks after initiation of steroid therapy. None of the patients who received prophylactic TMP-SMX therapy developed PCP even if the CD4+ lymphocyte count was less than 200/ μ l.

Conclusion Interstitial pneumonia patients receiving glucocorticoid therapy can benefit from TMP-SMX prophylaxis against PCP. Development of PCP cannot be ruled out in patients with a CD4+ lymphocyte count of greater than 200/ μ l.

Key words: interstitial pneumonia, pneumocystis pneumonia, circulating CD4+ lymphocyte count, prophylaxis with trimethoprim-sulfamethoxazole, beta-glucan

(DOI: 10.2169/internalmedicine.47.0402)

Introduction

Although glucocorticoids and immunosuppressants are widely used for the treatment of idiopathic interstitial pneumonia (1), as well as that associated with connective tissue diseases and vascular disorders (2), glucocorticoid/immunosuppressant therapy has adverse effects such as the occurrence of opportunistic infections in the lungs, including *Pneumocystis jiroveci* pneumonia (PCP), other fungal infections, and cytomegalovirus infection (3, 4). Because of the risk of opportunistic infection during the treatment of inter-

stitial pneumonia, prophylactic intervention against infection may lead to a better outcome of glucocorticoid/immunosuppressant therapy.

In this study, we retrospectively evaluated the efficacy of trimethoprim-sulfamethoxazole (TMP-SMX) for prophylaxis of PCP during glucocorticoid and/or immunosuppressant therapy for interstitial pneumonia.

Materials and Methods

This study was a retrospective analysis of 74 patients with interstitial pneumonia (IP) who were admitted to the Depart-

¹Department of Respiratory Medicine, Tokyo Metropolitan Hiroo General Hospital, Tokyo and ²Division of Pulmonary Diseases, Infection, and Oncology, Nippon Medical School, Tokyo

Received for publication June 23, 2007; Accepted for publication September 8, 2007

Correspondence to Dr. Arata Azuma, a-azuma@nms.ac.jp